Register for a Study

Register for a Study

Your Name (required)

Your Email (required)

Phone

Study of Interest:

 Autism (children and adolescents) ADHD Migrane- ACT: Preventative Treatment for Chronic Migraine in Teens Migrane- FORWARD: Open-label Study for Adults with Chronic Migraine Migrane- New Class of Oral Medication for Chronic Migraine Prevention Multiple Sclerosis Redefine: Autoinjectors in patients with RRMS Multiple Sclerosis - Laquinamod for PPMS, Phase 2 Multiple Sclerosis - Aspire: Botox for spasticity Multiple Sclerosis - Oral, extended-release baclofen Opioid Induced Constipation

Comments/Questions

Our Current Studies

ADHD

Currently enrolling for an ADHD study

See if you qualify for our ADHD study.

Autism

For children and adolescents

Currently Enrolling: Oral medication for children and adolescents aged 6 to 17 years with Irritability associated with Autistic Disorder.

Migraine

FORWARD: Open-label Study for Adults with Chronic Migraine

Comparing Preventative Treatment Options for Chronic Migraine: BOTOX® vs. Topiramate

Migraine

New Class of Oral Medication for Chronic Migraine Prevention

Evaluating the Efficacy and Safety of AMG 334 for Migraine Prevention + (Second phase of study includes a long-term, open-label extension study)

Migraine

ACT: Preventative Treatment for Chronic Migrane in Teens

A Clinical Trial to Evaluate BOTOX® as a Preventative Treatment for Chronic Migraines in Adolescents.

Multiple Sclerosis

REDEFINE: Easy-of-Use with Rebif Rebidose and Rebiject Autoinjectors in Patients with RRMS

Clinical Trials Identifier: NCT02019550

Multiple Sclerosis

Laquinamod for PPMS, Phase 2

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

Multiple Sclerosis

ASPIRE: Botox for Spasticity

Clinical Trials Identifier NCT01930786

Multiple Sclerosis

Oral, Extended-Release Baclofen

Clinical Trials Identifier NCT01457352

Opioid Induced Constipation

Currently Enrolling for an Opioid Induced Constipation study

See if you qualify for our Opioid Induced Constipation study